Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 4/2017

Ausgabe 4/2017

Inhaltsverzeichnis ( 16 Artikel )

11.03.2017 | PRECLINICAL STUDIES | Ausgabe 4/2017

Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice

Chii Chii Chew, Salby Ng, Yun Lee Chee, Teng Wai Koo, Ming Hui Liew, Evelyn Li-Ching Chee, Pilar Modamio, Cecilia Fernández, Eduardo L. Mariño, Ignacio Segarra

17.03.2017 | PRECLINICAL STUDIES | Ausgabe 4/2017

Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft

Nataly Tarasenko, Abraham Nudelman, Gabriela Rozic, Suzanne M. Cutts, Ada Rephaeli

27.03.2017 | PRECLINICAL STUDIES | Ausgabe 4/2017

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells

Yi-Yen Yeh, Jing-Ping Liou, Yueh-Lun Lee, John Yi-Chung Lin, Huei-Mei Huang

10.04.2017 | PRECLINICAL STUDIES | Ausgabe 4/2017

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

Valentine Heidelberger, François Goldwasser, Nora Kramkimel, Anne Jouinot, Olivier Huillard, Pascaline Boudou-Rouquette, Johan Chanal, Jennifer Arrondeau, Nathalie Franck, Jérôme Alexandre, Benoît Blanchet, Karen Leroy, Marie-Françoise Avril, Nicolas Dupin, Sélim Aractingi

04.02.2017 | PHASE I STUDIES | Ausgabe 4/2017

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

Patricia M. LoRusso, Mrinal Gounder, Shadia I. Jalal, Valérie André, Siva Rama Prasad Kambhampati, Nick Loizos, Jennifer Hall, Timothy R. Holzer, Aejaz Nasir, Jan Cosaert, John Kauh, E. Gabriela Chiorean

10.01.2017 | PHASE I STUDIES | Ausgabe 4/2017 Open Access

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

Hideo Saka, Chiyoe Kitagawa, Yoshihito Kogure, Yasuo Takahashi, Koshi Fujikawa, Tamotsu Sagawa, Satoru Iwasa, Naoki Takahashi, Taro Fukao, Catherine Tchinou, Dónal Landers, Yasuhide Yamada

19.01.2017 | PHASE I STUDIES | Ausgabe 4/2017

A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

Jianming Xu, Yingxin Li, Xing Sun, Dongsheng Zhang, Rongrui Liu, Samira Ziti-Ljajic, Dongmei Shi, Fengying Xue, Nathalie Le bail, Ruihua Xu

20.01.2017 | PHASE I STUDIES | Ausgabe 4/2017

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

Antonio Jimeno, Manish R. Sharma, Sergio Szyldergemajn, Lia Gore, David Geary, Jennifer R. Diamond, Carlos Fernandez Teruel, Arturo Soto Matos-Pita, Jorge Luis Iglesias, Martin Cullell-Young, Mark J. Ratain

31.01.2017 | PHASE I STUDIES | Ausgabe 4/2017

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II

C.M. Nijenhuis, L. Lucas, H. Rosing, A.D.R. Huitema, M. Mergui-Roelvink, G. C. Jamieson, J.A. Fox, D.R. Mould, J.H.M. Schellens, J.H. Beijnen

28.03.2017 | PHASE II STUDIES | Ausgabe 4/2017

Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS

Emily Chan, Laura W. Goff, Dana B. Cardin, Kristin Ancell, Stephen James Smith, Jennifer G. Whisenant, Fei Ye, Jordan D. Berlin

03.05.2017 | PHASE II STUDIES | Ausgabe 4/2017 Open Access

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

Tetsuhide Ito, Yoshitaka Honma, Susumu Hijioka, Atsushi Kudo, Akira Fukutomi, Akira Nozaki, Yasutoshi Kimura, Fuyuhiko Motoi, Hiroyuki Isayama, Izumi Komoto, Seiichi Hisamatsu, Akihiro Nakajima, Akira Shimatsu

16.03.2017 | REVIEW | Ausgabe 4/2017

Lung cancer and β-glucans: review of potential therapeutic applications

Raheleh Roudi, Shahla Roudbar Mohammadi, Maryam Roudbary, Monireh Mohsenzadegan

11.03.2017 | REVIEW | Ausgabe 4/2017

Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis

Giandomenico Roviello, Chiara Pacifico, Paola Corona, Daniele Generali

03.02.2017 | SHORT REPORT | Ausgabe 4/2017

Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib

Andrea Necchi, Giulia Pintarelli, Daniele Raggi, Patrizia Giannatempo, Francesca Colombo

20.03.2017 | SHORT REPORT | Ausgabe 4/2017

Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

Hisato Kawakami, Junko Tanizaki, Kaoru Tanaka, Koji Haratani, Hidetoshi Hayashi, Masayuki Takeda, Ken Kamata, Mamoru Takenaka, Masatomo Kimura, Takaaki Chikugo, Takao Sato, Masatoshi Kudo, Akihiko Ito, Kazuhiko Nakagawa

09.06.2017 | Erratum | Ausgabe 4/2017

Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

Valentine Heidelberger, François Goldwasser, Nora Kramkimel, Anne Jouinot, Olivier Huillard, Pascaline Boudou-Rouquette, Johan Chanal, Jennifer Arrondeau, Nathalie Franck, Jérôme Alexandre, Benoît Blanchet, Karen Leroy, Marie-Françoise Avril, Nicolas Dupin, Sélim Aractingi

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise